Apoptosis signal-regulating kinase inhibitors

Abstract

The present invention relates to compounds of Formula (I): wherein X 1 , X 2 , X 3 , X 4 , X 5 , R , R 1 , R 2 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

What is claimed is: 
     
       1. A compound selected from the group consisting of:
 4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(4,4,4-trifluoro-3-hydroxybutan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; 
 (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(3-methylbutan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; 
 (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; 
 4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-isopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; 
 (S)-4-(4-cyclopropyl-1H-imidazol-1-yl)-5-methyl-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; and 
 (S)-4-(4-tert-butyl-1H-imidazol-1-yl)-5-methyl-N-(2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
       2. The compound selected from the group consisting of:
 6-cyclopropyl-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-3,4′-bipyridine-2′-carboxamide; 
 N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-3,4′-bipyridine-2′-carboxamide; 
 4-(4-cyclopropyl-H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)picolinamide, and 
 4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(2-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-4-yl)-5-methylpicolinamide; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
       3. The compound selected from the group consisting of:
 4-(1H-benzo[d]imidazol-1-yl)-N-(4-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-2-yl)picolinamide; 
 N-(4-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-2-yl)-3,4′-bipyridine-2′-carboxamide; and 
 N-(4-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)thiazol-2-yl)-6-methoxy-3,4′-bipyridine-2′-carboxamide; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
       4. A pharmaceutical composition comprising an a therapeutically effective amount of one or more compounds according to  claim 1  and a pharmaceutically acceptable excipient. 
     
     
       5. A pharmaceutical composition comprising an a therapeutically effective amount of one or more compounds according to  claim 2  and a pharmaceutically acceptable excipient. 
     
     
       6. A pharmaceutical composition comprising an a therapeutically effective amount of one or more compounds according to  claim 3  and a pharmaceutically acceptable excipient. 
     
     
       7. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount is from 1 mg to 2 g. 
     
     
       8. The pharmaceutical composition of claim 5, wherein the therapeutically effective amount is from 1 mg to 2 g. 
     
     
       9. The pharmaceutical composition of claim 6, wherein the therapeutically effective amount is from 1 mg to 2 g.